ArticleCancer informatics2026
Integrative Analysis of Steroid Metabolism-Based Molecular Subtypes Reveals Prognostic Subtypes and Therapeutic Implications in Gastric Cancer.
Article in Cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify steroid metabolism-related molecular subtypes, investigate the gene expression patterns of these subtypes, and construct a prognostic risk model as well as predict therapeutic response in gastric cancer. Methods: We analyzed 410 TCGA-STAD and 483 GSE84437 gastric cancer samples. Unsupervised consensus clustering based on steroid metabolism-related genes identified molecular subtypes. Differential expression and functional enrichment analyses (GO, KEGG, GSEA) were performed. Prognostic genes were intersected with survival-associated genes, and a Lasso-Cox regression model was used to build a seven-gene risk score. Immune infiltration, tumor mutational burden (TMB), immune checkpoint expression, and drug sensitivity were evaluated. Results: Two steroid metabolism-related gastric cancer subtypes were identified, with steroid-metabolism-poor prognosis subtype showing poorer overall survival. Differential expression analysis revealed 1,709 genes enriched in immune regulation, calcium signaling, cell adhesion, and extracellular matrix remodeling. Seven key genes (PRICKLE1, SERPINE1, APOD, RIMS1, GLP2R, CDH19, GRP) were used to construct a risk score, which correlated with advanced stage, steroid-metabolism-poor prognosis subtype subtype, and worse survival, and was an independent prognostic factor. High-risk and steroid-metabolism-poor prognosis subtype tumors displayed higher immune infiltration and immune scores, lower TMB, and upregulated immune checkpoint genes, indicating an immunosuppressive microenvironment. Drug sensitivity differed across subtypes and risk groups, suggesting potential implications for personalized therapy. Conclusions: Steroid metabolism defines molecular heterogeneity, immune features, and prognosis in gastric cancer. The seven-gene risk model provides a reliable tool for survival prediction and may guide personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.